Forebrain regions affected by lateral parabrachial nucleus serotonergic mechanisms that influence sodium appetite.
Blockade of serotonergic receptors in the lateral parabrachial nucleus (LPBN), via bilateral injections of nonselective 5-hydroxytryptamine (5-HT)(1/2)-receptor antagonist, methysergide causes a robust sodium appetite. Our aim was to elucidate which brain regions are activated when serotonergic pathways to the LPBN are blocked and combined with subcutaneous injection of isoproterenol causing a salt appetite. In the experimental group, conscious rats were administered methysergide (4 microg/0.2 microl) injected bilaterally into the LPBN. Control groups included rats administered with injections of vehicle bilaterally into the LPBN, rats administered methysergide into injection sites outside the LPB region, and rats that did not undergo surgery. Each group was treated with a subcutaneous injection of isoproterenol (30 microg/kg), a beta-adrenergic agonist, and NaCl and water intakes were measured over 2h. Bilateral injections of methysergide into the LPBN followed by subcutaneous isoproterenol induced a strong intake of 0.3M NaCl (p<0.01) compared with all controls. Greater numbers of c-Fos-positive stained nuclei were observed in all brain regions assessed. The extended amygdala is rich in AT(1) receptors and ablation of these regions has been shown to reduce sodium appetite; therefore, neurons in these sites, and to a lesser extent the lamina terminalis, are likely primary targets of an inhibitory mechanism arising from the LPBN that acts to modulate sodium appetite.
Davern
Pamela J
PJ
Howard Florey Institute, University of Melbourne, Parkville, Victoria, Australia. pamela.davern@bakeridi.edu.au
McKinley
Michael J
MJ
D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000818:Animals; D001069:Appetite Regulation / Q000502:physiology*; D004326:Drinking / Q000187:drug effects / Q000502:physiology*; D007276:Injections, Intraventricular; D007279:Injections, Subcutaneous; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D008784:Methysergide / Q000008:administration & dosage; D016548:Prosencephalon / Q000502:physiology*; D016760:Proto-Oncogene Proteins c-fos / Q000187:drug effects* / Q000276:immunology; D051381:Rats; D011920:Rats, Inbred WF; D017207:Rats, Sprague-Dawley; D044282:Receptor, Serotonin, 5-HT1A / Q000378:metabolism; D044348:Receptors, Serotonin, 5-HT2 / Q000378:metabolism; D012249:Rhombencephalon / Q000187:drug effects / Q000502:physiology*; D058829:Serotonin 5-HT1 Receptor Antagonists; D058830:Serotonin 5-HT2 Receptor Antagonists; D012702:Serotonin Antagonists / Q000008:administration & dosage; D012965:Sodium Chloride / Q000378:metabolism; D014867:Water / Q000378:metabolism
D000318:Adrenergic beta-Agonists; D016760:Proto-Oncogene Proteins c-fos; D044348:Receptors, Serotonin, 5-HT2; D058829:Serotonin 5-HT1 Receptor Antagonists; D058830:Serotonin 5-HT2 Receptor Antagonists; D012702:Serotonin Antagonists; D014867:Water; D044282:Receptor, Serotonin, 5-HT1A; D012965:Sodium Chloride; D007545:Isoproterenol; D008784:Methysergide